Orexigen Therapeutics to price public offering of common shares

Credit Suisse, BofA Merrill Lynch and Leerink Swann assisting with sale

By Devika Patel

Knoxville, Tenn., Oct. 24 - Orexigen Therapeutics, Inc. plans to price a public offering of common stock with a greenshoe option, according to a preliminary prospectus supplement filed Wednesday with the Securities and Exchange Commission.

Credit Suisse, BofA Merrill Lynch and Leerink Swann are assisting.

Proceeds will be used for preparation of the company's resubmission of its NDA for lead product candidate, Contrave, as well as for regulatory submissions in the European Union and pre-commercialization activities for Contrave.

The company may also use the proceeds for working capital and other general corporate purposes.

The biopharmaceutical company is based in La Jolla, Calif.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.